This post was originally published on this site

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by stock analysts at TheStreet from a “c” rating to a “b-” rating in a report released on Tuesday, TheStreetRatingsTable reports.

SUPN has been the subject of several other reports. ValuEngine cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 8th. BidaskClub raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $26.75.

Shares of SUPN stock opened at $26.42 on Tuesday. The stock has a market capitalization of $1.39 billion, a PE ratio of 11.95 and a beta of 1.39. The firm has a 50 day moving average of $22.72 and a two-hundred day moving average of $22.31. Supernus Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $27.55. The company has a quick ratio of 1.94, a current ratio of 2.07 and a debt-to-equity ratio of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, November 3rd. The specialty pharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.47. The business had revenue of $155.10 million during the quarter, compared to analysts’ expectations of $130.76 million. Supernus Pharmaceuticals had a net margin of 27.85% and a return on equity of 19.44%. The company’s revenue for the quarter was up 52.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.54 EPS. Analysts expect that Supernus Pharmaceuticals will post 1.41 EPS for the current fiscal year.

In related news, CMO Stefan K.F. Schwabe sold 53,653 shares of the business’s stock in a transaction on Monday, December 14th. The shares were sold at an average price of $21.87, for a total value of $1,173,391.11. Following the completion of the sale, the chief marketing officer now directly owns 52,772 shares of the company’s stock, valued at $1,154,123.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Gregory S. Patrick sold 5,000 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $23.00, for a total transaction of $115,000.00. Following the completion of the sale, the chief financial officer now directly owns 49,463 shares of the company’s stock, valued at $1,137,649. The disclosure for this sale can be found here. Over the last three months, insiders sold 120,000 shares of company stock valued at $2,613,110. 6.57% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. Sei Investments Co. grew its position in Supernus Pharmaceuticals by 10.5% during the third quarter. Sei Investments Co. now owns 240,862 shares of the specialty pharmaceutical company’s stock worth $5,020,000 after buying an additional 22,831 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at approximately $760,000. Voloridge Investment Management LLC lifted its stake in Supernus Pharmaceuticals by 4.8% in the third quarter. Voloridge Investment Management LLC now owns 149,800 shares of the specialty pharmaceutical company’s stock valued at $3,122,000 after acquiring an additional 6,799 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Supernus Pharmaceuticals by 14.2% in the third quarter. Arrowstreet Capital Limited Partnership now owns 179,631 shares of the specialty pharmaceutical company’s stock valued at $3,744,000 after acquiring an additional 22,313 shares during the last quarter. Finally, State of Tennessee Treasury Department lifted its stake in Supernus Pharmaceuticals by 11.5% in the second quarter. State of Tennessee Treasury Department now owns 39,269 shares of the specialty pharmaceutical company’s stock valued at $933,000 after acquiring an additional 4,053 shares during the last quarter. Institutional investors own 94.81% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy.

Read More: Price Target

Receive News & Ratings for Supernus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.